Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely.
Tag Archive for: bebtelovimab
Eli Lilly and Co. missed Wall Street estimates for sales of its keenly-watched drug Mounjaro as well as older diabetes treatment, overshadowing a better-than-expected 2023 profit forecast.
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
As per the modified supply agreement with the government, Lilly will provide an additional 150,000 doses of bebtelovimab for about $275 million. The drug has also shown effectiveness against the Omicron variant.
